Off-Label Marketing and the Addiction Crisis No One Expected
Gabapentin (brand name Neurontin, and the generic) was approved by the FDA for epilepsy (1993) and post-herpetic neuralgia (2002). What it was not approved for (yet what drove the vast majority of its prescriptions) was an enormous range of off-label uses: chronic pain, fibromyalgia, migraine, alcohol withdrawal, anxiety, and bipolar disorder. By 2019, gabapentin was the fifth most prescribed drug in the United States, with over 64 million prescriptions annually, and it was dispensed predominantly for conditions the FDA had never evaluated or approved.
The original manufacturer, Pfizer subsidiary Warner-Lambert, pleaded guilty in 2004 to criminal charges of illegal off-label marketing of Neurontin and paid $430 million in criminal and civil penalties. The government established that Warner-Lambert had conducted a systematic, multi-year campaign to promote Neurontin for unapproved uses, including fabricating clinical trial data and bribing physicians. Consulting pharmaceutical liability attorneys can help evaluate your specific claim. Despite this criminal resolution, gabapentin prescriptions continued climbing for decades, driven by generic manufacturers who themselves face allegations of perpetuating the off-label marketing infrastructure developed by the original manufacturer.
The Addiction Problem: What Wasn't Disclosed
Gabapentin's prescribing information has historically characterized its abuse potential as low and its dependency risks as minimal compared to opioids. This characterization, plaintiffs allege, is materially misleading. Research published in peer-reviewed journals including Addiction and Drug and Alcohol Dependence documents that gabapentin produces physical dependence with withdrawal symptoms (including anxiety, insomnia, nausea, and seizures) that can be severe, particularly at the high doses common in chronic pain treatment. When combined with opioids, gabapentin amplifies opioid respiratory depression, contributing to overdose deaths.
The CDC's 2022 clinical practice guideline for prescribing opioids noted that gabapentinoids (gabapentin and pregabalin) carry misuse potential and warned clinicians about the combination with opioids. Multiple states (including Kentucky, Tennessee, and Michigan) have added gabapentin to their controlled substance schedules, an administrative recognition that the drug's abuse potential was underestimated in its federally approved labeling. These regulatory actions directly support the failure-to-warn theory in the gabapentin litigation.
The Legal Claims and Who Is Being Sued
Current gabapentin litigation targets both the pharmaceutical manufacturers and the pharmacy benefit managers (PBMs) and insurers who, plaintiffs allege, enabled the flood of off-label prescriptions by covering gabapentin broadly without clinical effectiveness evidence for most off-label uses. The novel PBM theory, that benefit managers who approved off-label gabapentin reimbursement share in responsibility for the resulting addiction crisis, is still being developed in courts and has not yet achieved the sustained success of the manufacturer-focused theories.
States and municipalities are pursuing RICO and public nuisance claims against gabapentin manufacturers and distributors in the tradition of opioid litigation. Individual personal injury claims focus on patients who became addicted to gabapentin or suffered serious withdrawal complications and were not warned of these risks. Related: MDL litigation structure comparison and all active pharmaceutical MDLs.
Who Can File a Gabapentin Injury Claim?
The gabapentin litigation is still in early formation as of 2026. The clearest cases involve: individuals prescribed gabapentin for off-label conditions (anything other than epilepsy or post-herpetic neuralgia) who developed physical dependence or addiction; patients who experienced severe withdrawal symptoms upon discontinuation that required hospitalization; and estates of individuals who died from gabapentin-opioid combination overdoses. Pharmacy records, prescription histories, and medical records documenting withdrawal and addiction treatment are the core evidence. Consult a pharmaceutical litigation attorney for case-specific evaluation.
How to File a Claim or Get Help
If you believe you qualify based on the eligibility criteria outlined above, the next step is a free consultation with an experienced attorney who handles this case type. Most plaintiff-side attorneys offer no-cost initial evaluations and work on contingency, meaning you pay nothing unless your case results in a recovery. Bring any relevant documentation to your consultation: receipts, medical records, correspondence, or any evidence of the harm you experienced.
To stay current on case developments, claim deadlines, and settlement news, bookmark this page and subscribe to the LawsuitWatch newsletter. We update our coverage as new court filings, settlement announcements, and eligibility changes are made public.
Free Legal Evaluation
Do You Qualify to File a Claim?
Our network of verified plaintiff attorneys offers free, no-obligation case evaluations. Contingency fee representation means you pay nothing unless you win.
Join the Gabapentin Lawsuit: Latest Updates & Legal Analysis: Frequently Asked Questions
Answers to the most common questions about this case and your legal options.
What is gabapentin and why is it controversial?
Gabapentin is an anticonvulsant approved for epilepsy and post-herpetic neuralgia pain. It became controversial because the original manufacturer committed criminal fraud to promote it for dozens of unapproved uses, and because it developed an addiction and misuse problem not adequately reflected in its labeling, contributing to overdose deaths, particularly when combined with opioids.
Is gabapentin an opioid?
No. Gabapentin is not an opioid, it works through a different mechanism (calcium channel binding) and is not a controlled substance federally, though several states have added it to their controlled substance schedules. However, gabapentin amplifies opioid effects and respiratory depression, and has its own dependence profile that the lawsuit alleges was inadequately disclosed.
Can I stop taking gabapentin if I want to join the lawsuit?
Do not abruptly discontinue gabapentin without medical supervision, withdrawal can include seizures in some patients. Your medication decisions should be made in consultation with your prescribing physician. Your legal claims are independent of whether you continue or discontinue the medication.
What evidence do I need for a gabapentin lawsuit?
Useful evidence includes: prescription records showing when you started gabapentin and for what condition, evidence that it was prescribed off-label (not for epilepsy or post-herpetic neuralgia), medical records documenting dependence symptoms or withdrawal complications, and records of any addiction treatment. An attorney can subpoena pharmacy and medical records on your behalf.
Is there a gabapentin class action or is each case individual?
As of mid-2026, gabapentin litigation is proceeding as individual cases and government (state/municipality) mass actions rather than a consumer class action. Individual patient cases are evaluated based on specific injury, exposure history, and causation. An MDL may be established as the case volume grows.
Legal Disclaimer
This article is for general informational purposes only and does not constitute legal advice or create an attorney-client relationship. Lawsuit eligibility, settlement amounts, and case status are subject to change as litigation develops. Always consult a licensed attorney in your jurisdiction before making legal decisions. LawsuitWatch is an independent journalism publication and is not a law firm. LawsuitWatch may receive referral compensation from affiliated legal service providers, which does not influence editorial content.